missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Specifications
| Accession Number | ADHR; FGF; Fgf23; FGF-23; FGFN; Fibroblast growth factor; Fibroblast growth factor 23; Fibroblast growth factor 23 C-terminal peptide; Fibroblast growth factor 23 N-terminal peptide; HPDR2; HYPF; Phosphatonin; PHPTC; tumor-derived hypophosphatemia inducing factor; Tumor-derived hypophosphatemia-inducing factor; UNQ3027/PRO9828 |
|---|---|
| Assay Range | 0.3 to 75 ng/mL |
| Assay Sensitivity | 0.3 ng/mL |
| Conjugate | HRP |
| Product Type | ELISA |
| Catalog Number | Mfr. No. | Quantity | Price | Quantity & Availability | |||||
|---|---|---|---|---|---|---|---|---|---|
| Catalog Number | Mfr. No. | Quantity | Price | Quantity & Availability | |||||
EH189RBX5
|
Invitrogen™
EH189RBX5 |
5 x 96 Tests |
Each for $4,420.00
|
|
|||||
|
EH189RB
|
Invitrogen™
EH189RB |
96 Tests |
Each for $890.00
|
|
|||||
Description
Human FGF-23 quantitates human FGF-23 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human FGF-23.
The protein encoded by this gene is a member of the fibroblast growth factor family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. The product of this gene inhibits renal tubular phosphate transport. This gene was identified by its mutations associated with autosomal dominant hypophosphatemic rickets, an inherited phosphate wasting disorder. Abnormally high level expression of this gene was found in oncogenic hypophosphatemic osteomalacia, a phenotypically similar disease caused by abnormal phosphate metabolism. Mutations in this gene have also been shown to cause familial tumoral calcinosis with hyperphosphatemia.Specifications
| ADHR; FGF; Fgf23; FGF-23; FGFN; Fibroblast growth factor; Fibroblast growth factor 23; Fibroblast growth factor 23 C-terminal peptide; Fibroblast growth factor 23 N-terminal peptide; HPDR2; HYPF; Phosphatonin; PHPTC; tumor-derived hypophosphatemia inducing factor; Tumor-derived hypophosphatemia-inducing factor; UNQ3027/PRO9828 | |
| 0.3 ng/mL | |
| ELISA | |
| Colorimetric Microplate Reader | |
| FGF23 | |
| <10 | |
| HRP | |
| Plasma 50 μL, Serum 50 μL, Supernatant 50 μL | |
| FGF23 | |
| 4 hrs 45 mins |
| 0.3 to 75 ng/mL | |
| HRP | |
| Plasma, Serum, Supernatant | |
| 8074 | |
| <12% | |
| Pre-coated 96 well plate, Standard, Assay Diluent concentrate, Biotinylated Detection Antibody, SAV-HRP, Wash Buffer, Chromogen, Stop Solution, Adhesive Plate Covers | |
| RUO | |
| 2°C to 8°C | |
| 1 hrs 20 mins |